Latest accounts payable for GMDA: $5.4M.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
Gamida Cell (GMDA) currently reports a accounts payable of $5.4M as of March 2024. That compares with $4.4M in the prior-year period — up 23.5% year over year. Use the charts on this page to explore Gamida Cell's accounts payable history and peer comparisons.
Gamida Cell's accounts payable increased from $4.4M to $5.4M — a 23.5% year-over-year increase (period ending March 2024). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.
Gamida Cell reported $5.4M in accounts payable as of March 2024. That compares with $4.4M in the prior-year period — up 23.5% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.
Start with the current accounts payable of $5.4M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Gamida Cell, and consider following GMDA for alerts when major investors trade the stock.
Gamida Cell is classified in the Healthcare sector. On accounts payable, it currently shows $5.4M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing GMDA with unrelated industries.